Cargando…
Metformin Pharmacogenomics: Current Status and Future Directions
The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variabi...
Autores principales: | Pawlyk, Aaron C., Giacomini, Kathleen M., McKeon, Catherine, Shuldiner, Alan R., Florez, Jose C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113063/ https://www.ncbi.nlm.nih.gov/pubmed/25060887 http://dx.doi.org/10.2337/db13-1367 |
Ejemplares similares
-
Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions
por: Halter, Jeffrey B., et al.
Publicado: (2014) -
Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG)
por: Bienfait, Karina, et al.
Publicado: (2021) -
Neuroscience education and research in Cameroon: Current status and future direction
por: Mbiydzenyuy, Ngala Elvis, et al.
Publicado: (2021) -
Telemedicine in Diabetic Retinopathy: Current Status and Future Directions
por: Das, Taraprasad, et al.
Publicado: (2015) -
American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome
por: Semenkovich, Clay F., et al.
Publicado: (2015)